HUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Revenue
HUTCHMED (China) Limited Sponsored ADR's revenue for fiscal 2025 was $548.5M, down 13.0% from $630.2M in fiscal 2024. Over the past ten years it has ranged from $178.2M (fiscal 2015) to $838.0M (fiscal 2023); the current reading is higher than 82% of that period. HUTCHMED (China) Limited Sponsored ADR ranks 5th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $548.5M | (12.96%) |
| FY2024 | $630.2M | (24.80%) |
| FY2023 | $838.0M | 96.52% |
| FY2022 | $426.4M | 19.73% |
| FY2021 | $356.1M | 56.21% |
| FY2020 | $228.0M | 11.27% |
| FY2019 | $204.9M | (4.31%) |
| FY2018 | $214.1M | (11.23%) |
| FY2017 | $241.2M | 11.63% |
| FY2016 | $216.1M | 21.25% |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR | $10.1B |
| PRGO Perrigo Company plc compare | $4.1B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| TRLV Trulieve Cannabis Corp. compare | $1.1B |
| ANIP ANI Pharmaceuticals, Inc. compare | $1.0B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $961.5M |
| XERS Xeris Biopharma Holdings, Inc. compare | $368.3M |
| ALVO Alvotech compare | $293.3M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on HCM
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement